Pictured: Scott Lowe
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Tuesday, September 30, 2014

In taking a new approach to finding treatments for hepatocellular carcinoma, MSK scientists have uncovered a potential drug target for this highly aggressive cancer.

Pictured: Paul Sabbatini
Q&A
By Esther Napolitano, BS, Science Writer/Editor  |  Wednesday, September 24, 2014

Medical oncologist Paul Sabbatini sheds light on how phase I clinical trials are conducted at Memorial Sloan Kettering and how to determine whether patients may be eligible for one.

In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, September 4, 2014

Researchers have created tiny structures called organoids from patients’ prostate tumors. These organoids will allow the study of tumors in greater detail and enable correlation of genetic mutations with drug response.

In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Monday, July 28, 2014

Memorial Sloan Kettering researchers have found a naturally occurring compound that can destroy cancer cells in mice by targeting MYC, a cancer-causing gene that has remained elusive until now.

Pictured: Gabriela Chiosis
Finding
By Celia Gittelson, BA  |  Thursday, July 17, 2014

A small molecule discovered at MSK called PU-H71 blocks the growth of cancer cells and enables doctors to image tumors.

Pictured: Daniel Heller
Video
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, March 27, 2014

The research team of chemist and engineer Daniel Heller creates new nanoscale materials that are specially designed to improve biological research or solve clinical problems.

Pictured: Michael Foley
Announcement
By Memorial Sloan Kettering  |  Thursday, December 5, 2013

A renowned chemist with 25 years of industry and academic experience, Michael Foley will lead a pioneering collaboration designed to speed the development of new drugs for people with cancer and other diseases.

Pictured: Clifford Hudis
Video
By Memorial Sloan Kettering  |  Friday, November 1, 2013

Medical oncologist Clifford Hudis says advances in immunology and molecular biology are leading to remarkable successes in cancer treatment.

Pictured: Laurie Glimcher, Craig Thompson, Marc Tessier-Lavigne & Tadataka Yamada
Announcement
By Jim Stallard, MA, Writer/Editor  |  Thursday, October 24, 2013

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.

Mouse glioblastoma tumor with phagocytic macrophages
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Tuesday, October 15, 2013

Memorial Sloan Kettering researchers say a drug that acts on noncancerous, tumor-infiltrating cells might provide a new treatment option for the most common and aggressive type of brain cancer.

Pictured: Derek Tan
Q&A
By Julie Grisham, MS, Science Writer/Editor  |  Monday, September 16, 2013

In this Q&A, Memorial Sloan Kettering chemist Derek Tan discusses why natural products offer inspiration for the development of new drugs.

Pictured: Robert J. Motzer
In the Clinic
By Maureen Salamon, BA, Freelance Writer  |  Thursday, August 22, 2013

An international study led by Memorial Sloan Kettering found that pazopanib (Votrient®) controls cancer as effectively as sunitinib (Sutent®) while improving patients’ quality of life.

Perspective
By Paul Sabbatini, MD, Deputy Physician-in-Chief for Clinical Research  |  Friday, July 26, 2013

The clinical trial remains our best tool to identify new therapies, but as with all tools, innovation is required if trials are to remain relevant.

Pictured: Three-dimensional structure of the protein mTOR
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, May 30, 2013

In an eagerly awaited study, Memorial Sloan Kettering researchers report on the molecular structure of mTOR, a protein commonly mutated in cancer.

Pictured: Charles Sawyers
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, April 30, 2013

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

Center News

Stay Informed

Get the latest information about cancer care and research every month.